Beatriz Paredes-Moreno

Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial

María Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela‐Silva et al. · The Lancet Regional Health - Americas · 2022 · 46 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials

María Eugenia-Toledo-Romaní, Leslyhana Verdecia-Sánchez, Meiby Rodríguez-González et al. · Vaccine · 2022 · 38 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomised, placebo-controlled phase 3 clinical trial

María Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela‐Silva et al. · medRxiv · 2021 · 31 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity

Sonia Pérez-Rodríguez, Meiby Rodríguez-González, Rolando Ochoa-Azze et al. · Vaccine · 2022 · 31 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +12

Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults

María Eugenia Toledo-Romaní, Mayra García-Carmenate, Leslyhana Verdecia-Sánchez et al. · Med · 2022 · 30 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +13